Table 1.
Patient baseline characteristics
| Tarextumab (n = 89) | Placebo (n = 88) | Total (n = 177) | |
|---|---|---|---|
| Median age, years (range) | 66 (34‐88) | 66 (40‐82) | 66 (34‐88) |
| Sex, n (%) | |||
| Male | 50 (56%) | 54 (61%) | 104 (59%) |
| Female | 39 (44%) | 34 (39%) | 73 (41%) |
| ECOG score, n (%) | |||
| 0 | 34 (38%) | 34 (39%) | 68 (38%) |
| 1 | 55 (62%) | 54 (61%) | 109 (62%) |
| CA 19‐9 Levels | |||
| 0 to ULN | 19 (21%) | 18 (20%) | 37 (21%) |
| >ULN to 59xULN | 24 (27%) | 26 (30%) | 50 (28%) |
| ≥59xULN | 46 (52%) | 44 (50%) | 90 (51%) |
| Primary pancreatic tumor location, n (%) a | |||
| Head | 39 (44%) | 37 (42%) | 76 (43%) |
| Body | 34 (38%) | 32 (36%) | 66 (37%) |
| Tail | 29 (33%) | 32 (36%) | 61 (35%) |
| Other | 10 (11%) | 9 (10%) | 19 (11%) |
| Current site(s) of metastasis, n (%) a | |||
| Pancreas | 86 (97%) | 83 (94%) | 169 (96%) |
| Liver | 76 (85%) | 78 (89%) | 154 (87%) |
| Lungs | 39 (44%) | 31 (35%) | 70 (40%) |
| Lymph nodes | 34 (38%) | 45 (51%) | 79 (45%) |
| Other | 23 (26%) | 24 (27%) | 47 (27%) |
| Kidney | 3 (3%) | 3 (3%) | 6 (3%) |
| Bone | 5 (6%) | 5 (6%) | 10 (6%) |
| Number of metastatic sites, n (%) | |||
| 1 | 1 (1%) | 1 (1%) | 2 (1%) |
| 2 | 28 (32%) | 27 (31%) | 55 (31%) |
| ≥3 | 60 (67%) | 59 (67%) | 119 (67%) |
| Prior surgery, n (%) | |||
| Yes | 6 (7%) | 6 (7%) | 12 (7%) |
| No | 83 (93%) | 82 (93%) | 165 (93%) |
| Prior radiotherapy, n (%) | |||
| Yes | 2 (2%) | 1 (1%) | 3 (2%) |
| No | 87 (98%) | 87 (99%) | 174 (98%) |
| Prior systemic therapy, n (%) b | |||
| Yes | 1 (1%) | 2 (2%) | 3 (2%) |
| No | 88 (99%) | 86 (98%) | 174 (98%) |
a
Patients may be included in more than one site of disease. Percentage may add up to more than 100%.
b
These patients received prior systemic therapy as adjuvant therapy.